Doxycycline windfall sweeps up Hikma
This article was originally published in Scrip
Executive Summary
Hikma Pharmaceuticals has for the second time this year upped its financial guidance for the full year. It now expects revenues to rise by around 17% in 2013, versus previous guidance of 13%.